Form 8-K EPIRUS Biopharmaceutical For: Nov 16

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Form 8-K EPIRUS Biopharmaceutical For: Nov 16

EPIRUS Biopharma (EPRS) Misses Q3 EPS by 8c; Updates on BOW015 as RA Treatment

November 16, 2015 8:40 AM EST

EPIRUS Biopharma (NASDAQ: EPRS) reported Q3 EPS of ($0.59), $0.08 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $221 million versus the consensus estimate of $500 thousand.

EPIRUS also announced the completion of manufacturing process lock and readiness for initiation of its pivotal global registration study. EPIRUS plans to initiate a global registration study for BOW015 (infliximab, reference biologic Remicade®ii) in active... More